| Adalimumab (n = 32) | Etanercept (n = 16) | Tocilizumab (n = 24) | Without biologic (n = 20) |
---|---|---|---|---|
Mean age, years | 53.5 ± 12.6 | 54.4 ± 7.8 | 56.8 ± 14.4 | 57.0 ± 11.4 |
Female proportion | 28 (87.5%) | 13 (81.3%) | 20 (83.3%) | 17 (85.0%) |
Disease duration, years | 13.4 ± 6.6 | 13.6 ± 9.0 | 13.0 ± 9.7 | 12.3 ± 5.8 |
Body mass index, kg/m2 | 24.8 ± 4.6 | 23.6 ± 4.5 | 24.5 ± 3.7 | 22.9 ± 2.9 |
RF positivity | 28 (87.5%) | 13 (81.3%) | 17 (70.8%) | 14 (70.0%) |
Anti-CCP positivity | 21 (65.6%) | 11 (68.8%) | 17 (70.8%) | 15 (75.0%) |
Baseline ESR, mm/1st hour | 33.5 ± 23.4 | 39.0 ± 36.0 | 42.5 ± 30.0 | 35.8 ± 22.1 |
Baseline DAS28 | 5.46 ± 0.94 | 5.48 ± 0.98 | 5.80 ± 0.85 | 5.12 ± 0.59 |
Daily steroid dose, mg/day | 6.3 ± 2.5 | 6.9 ± 1.9 | 7.4 ± 2.1 | 7.0 ± 2.2 |
DMARDs at baseline | Â | Â | Â | Â |
  MTX, weekly dose, mg | 12.0 ± 2.5 | 10.6 ± 3.7 | 11.5 ± 2.5 | 11.3 ± 2.8 |
  Sulfasalazine | 27 (84.4%) | 12 (75.0%) | 18 (75.0%) | 17 (85.0%) |
  Hydroxychloroquine | 24 (75.0%) | 12 (75.0%) | 19 (79.2%) | 18 (90.0%) |
  Cyclosporine | 6 (18.7%) | 4 (25.0%) | 5 (20.8%) | 7 (35.0%) |
Hypertension | 14 (43.8%) | 6 (37.5%) | 8 (33.3%) | 8 (40.0%) |
Antihypertensive Rx | 8 (25.0%) | 4 (25.0%) | 7 (29.2%) | 6 (30.0%) |
Diabetes mellitus | 2 (6.2%) | 1 (6.3%) | 1 (4.2%) | 1 (5.0%) |
Hypoglycemic Rx | 1 (3.1%) | 1 (6.3%) | 0 (0.0%) | 0 (0.0%) |
Current smoker | 3 (9.4%) | 2 (16.6%) | 3 (12.5%) | 3 (15.0%) |